Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Artificial intelligence-powered drug discovery is capturing breathless headlines, drug company deals, and investor capital, but the acceleration it promises will not happen overnight.
With neuroinflammation, fibrosis, genomics and apoptosis research to the fore, Johns Hopkins is ramping up its output of startups with a little help from Korea.
Mounting evidence of efficacy in metastatic breast cancer and other epithelial tumors is driving clinical and commercial investment in tumor-infiltrating lymphocytes.
Despite slow uptake in the clinic, liquid biopsy tests incorporating methylation and other signatures are showing increasingly compelling data for non-invasive detection of cancer.
Pancreatic cancer treatments are forging the path for a new line of agents that target the physical properties of a tumor and its surrounding microenvironment.
Microsoft unveils the first collaborations for its Station B, a platform to automate lab experiments so scientists can test and reproduce ever-more-complex designs.